✦ LIBER ✦

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

✍ Scribed by Richard A. Larson; Eric L. Sievers; Edward A. Stadtmauer; Bob Löwenberg; Elihu H. Estey; Hervé Dombret; Matthias Theobald; Dimitris Voliotis; John M. Bennett; Maria Richie; Lance H. Leopold; Mark S. Berger; Matthew L. Sherman; Michael R. Loken; Jacques J. M. van Dongen; Irwin D. Bernstein; Frederick R. Appelbaum; Mylotarg Study Group

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 258 KB
Volume: 104
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.21326

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

AAML03P1, a pilot study of the safety of

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia : A report from the Children's Oncology Group

✍ Todd M. Cooper; Janet Franklin; Robert B. Gerbing; Todd A. Alonzo; Craig Hurwitz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 385 KB 👁 1 views

Fractionated doses of gemtuzumab ozogami

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: A phase 1/2 study of the acute leukemia French association

✍ Hassan Farhat; Oumedaly Reman; Emmanuel Raffoux; Celine Berthon; Cécile Pautas; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views